In these short videos, Professors Evangelos Terpos and Hermann Einsele share key insights from their lecture on multiple myeloma at the prestigious 6th European Myeloma Network (EMN) Meeting, sponsored by Menarini Stemline.

 

Key topics include:

  • Individualised treatment in early relapse in multiple myeloma
  • Optimising the sequence of novel therapies from early relapse

 

Clinical takeaways

  • Although therapeutic advances in MM have improved outcomes, this has generated a wide range of patient profiles at early relapse  
  • There is a need for new targets/new drugs with a different MoA 
  • Many novel immunotherapies for R/R MM, including CAR-T cell therapy, bispecific antibodies and ADCs, are coming to earlier lines of treatment 
  • Selinexor is a first-in-class, oral XPO1 inhibitor with a unique MoA  
  • SVd may be a suitable treatment option for early relapsed patients previously treated with lenalidomide and daratumumab, as it offers a double MoA switch 
  • In the real-world setting, SVd is easy to manage with dose reductions and prophylactic use of drugs, resulting in good efficacy outcomes
  • To improve patient survival rates, we need to better understand the optimal sequencing of selinexor combinations across the novel immune therapies  

In these short videos, Professors Evangelos Terpos and Hermann Einsele share key insights from their lecture on multiple myeloma at the prestigious 6th European Myeloma Network (EMN) Meeting, sponsored by Menarini Stemline.

 

Key topics include:

  • Individualised treatment in early relapse in multiple myeloma
  • Optimising the sequence of novel therapies from early relapse

 

Clinical takeaways

  • There is a lack of clear SoC on the use, combination and sequencing of the growing number of MM treatment options, complicated by the heterogeneity of this population 
  • Immunotherapies can cause detrimental effects on the immune system, potentially causing T-cell exhaustion 
  • XPO1 inhibitors promote T-cell fitness and reduce T-cell exhaustion, and different studies have demonstrated the effect of selinexor on T-cell fitness
  • Incorporating selinexor combinations as BCMA-free regimens can enhance benefits and improve outcomes following prior BCMA-directed therapy by optimising treatment sequencing 

Programme summary
Watch the video now
Share this programme
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
Supporter Acknowledgement
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
I agree that this programme:

Was valuable to me

1/3
Programme summary
Watch the video now
Share this programme
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
Supporter Acknowledgement
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
I agree that this programme:

Was valuable to me

1/3

Other programmes of interest

publication Publication
Oncology 
LEAP-012 publication

Expert insights on multimodal treatment for intermediate HCC

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
video Video
Oncology Hemato-oncology 
Innovating relapsed refractory multiple myeloma care

Unmet needs, therapy management, and real-world experience

Experts
Assoc. Prof. María Victoria Mateos, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Elena Zamagni
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
interactive-patient-case Interactive patient case
Oncology 
NTRK fusion testing and treatment in pediatric sarcoma

Make decisions for a young patient during his cancer journey

Experts
Dr Theodore Laetsch
Endorsed by
NTRKers
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
interactive-patient-case Interactive patient case
Oncology 
Later-line treatment strategies in metastatic colorectal cancer (mCRC)

Rechallenge vs switching

Experts
Prof. Andrea Sartore-Bianchi
Endorsed by
DiCE ICAN international cancer advocacy network
  • clock 15 MIN
  • calendar Jun 2025

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025

Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Prof. Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED